Daurismo for Newly Diagnosed AML

Daurismo (glasdegib, Pfizer)

Indications: Newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older and have comorbidities that preclude use of intensive induction chemotherapy

Dosage: 100 mg orally, once daily.

Contraindications: None

Click here for more prescribing information